ReviewVaccines2024
Use of Measles and Rubella Rapid Diagnostic Tests to Improve Case Detection and Targeting of Vaccinations.
Review in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- A target product profile and roadmap for Japanese encephalitis diagnostics in endemic areas in the context of other flaviviruses.PLoS neglected tropical diseases · 2026Article
- Measles-rubella surveillance and its facilitators and barriers in Bagmati province, Nepal: a mixed methods study.BMC infectious diseases · 2026Article
- Challenges for the effectiveness of infectious disease interventions during global change.Communications health · 2026Article
- Utilizing rapid diagnostic tests in infectious disease surveillance and response in humanitarian emergencies.Frontiers in public health · 2026Review
- Diagnostic Approaches for Measles Virus: Methods, Advances, and Ongoing Challenges.Pathogens (Basel, Switzerland) · 2025Review
- Measles and rubella: From global health challenges to advancements in molecular diagnostics in the elimination era.Molecular therapy. Nucleic acids · 2025Review
- Epidemiology, clinical overview, and potential risk of a new pandemic of measles virus.Infectious diseases & immunity · 2025Review
- Measles Vaccination Coverage and Anti-Measles Herd Immunity Levels in the World and WHO Regions Worsened from 2019 to 2023.Vaccines · 2025Article
- New approaches to measles eradication, with special reference to Africa.The Pan African medical journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Efforts to control and eliminate measles and rubella are aided by high-quality surveillance data-supported by laboratory confirmation-to guide decision-making on routine immunization strategies and locations for conducting preventive supplementary immunization activities (SIAs) and outbreak response. Important developments in rapid diagnostic tests (RDTs) for measles and rubella present new opportunities for the global measles and rubella surveillance program to greatly improve the ability to rapidly detect and respond to outbreaks. Here, we review the status of RDTs for measles and rubella Immunoglobulin M (IgM) testing, as well as ongoing questions and challenges regarding the operational use and deployment of RDTs as part of global measles and rubella surveillance. Efforts to develop IgM RDTs that can be produced at scale are underway. Once validated RDTs are available, clear information on the benefits, challenges, and costs of their implementation will be critical for shaping deployment guidance and informing country plans for sustainably deploying such tests. The wide availability of RDTs could provide new programmatic options for measles and rubella elimination efforts, potentially enabling improvements and flexibility for testing, surveillance, and vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.